Endpoint, IVRS Central Management - IMSC
Endpoint, IVRS Central Management - IMSC is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
A Phase 3b, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other luspatercept (ACE-536, also known as BMS 986346) clinical trials.
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Following FDA IND review, the protocol broadened exclusions for factors associated with QTc prolongation and torsades de pointes risk, revised the dose-limiting-toxicity definition, and reduced the Part 1 target toxicity rate from 30% to 20%.
- The protocol reduced Part 2 cohort expansion from 100 to 20 participants per dosing schedule, added 6/28- and 20/28-day dosing schedules for Part 2, and reduced the overall planned study population.
- Part 2 enrollment suspension rules based on prespecified safety and efficacy criteria were added.
- A 2022 amendment aligned post-treatment contraception, pregnancy-testing, pregnancy-counselling, and gamete-donation guidance with CTFG recommendations; the sponsor stated these changes were not driven by new safety data or health-authority feedback.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2a Study to Evaluate the Safety and Pharmacokinetics of Luspatercept (ACE-536) in Pediatric Participants with Beta (β) Thalassemia.
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Endpoint, IVRS Central Management - IMSC?
The 2026-10-09 snapshot links Endpoint, IVRS Central Management - IMSC to 3 distinct CTIS trials. Recorded services include Patient registration, IP supply, IVRS30 – treatment randomisation. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Endpoint, IVRS Central Management - IMSC?
The most frequently recorded therapeutic areas are Blood Disorders, Haematological Malignancies, Genetic and Congenital Disorders. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Endpoint, IVRS Central Management - IMSC conducted?
The linked trials record locations in 9 countries, including Germany, Spain, Greece, Italy, Belgium. These are trial locations, not confirmed office locations or countries where Endpoint, IVRS Central Management - IMSC delivered services.
What can this page tell me about Endpoint, IVRS Central Management - IMSC's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Endpoint, IVRS Central Management - IMSC. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Endpoint, IVRS Central Management - IMSC